E-viri
Recenzirano
-
Moschini, Marco; Soria, Francesco; Klatte, Tobias; Wirth, Gregory J; Özsoy, Mehmet; Gust, Killian; Briganti, Alberto; Roupret, Morgan; Susani, Martin; Haitel, Andrea; Shariat, Shahrokh F
Clinical genitourinary cancer, 04/2017, Letnik: 15, Številka: 2Journal Article
Micro-Abstract Neoadjuvant chemotherapy (NAC) has been demonstrated to be effective in prospective randomized trials for cT2-cT4a N0 patients. However, this benefit was more evident in patients with clinical stage ≥ T3 disease. On the other hand, toxicity grade 3 and 4 were reported in 35% and 37% of patients who underwent NAC. Following these considerations, we validate here the preoperative risk model proposed by Culp et al as a fundamental tool in the preoperative prediction of patients who will benefit more from NAC administration.
